Journal Home
Search for

Volume 13, Issue 1, Pages 36-42 (January 2010)


View previous. 6 of 105 View next.

How Activity of Inflammatory Bowel Disease Influences Bone Loss

Zeljka Crncevic Orlic1Corresponding Author Informationemail address, Tamara Turk1, Brankica Mijandrusic Sincic2, Davor Stimac2, Olga Cvijanovic3, Ivana Maric3, Maja Ilic Tomas4, Dubravka Jurisic-Erzen1, Vanja Licul2, Dragica Bobinac3

Received 22 March 2009; received in revised form 9 December 2009; accepted 10 December 2009.

Abstract 

Bone loss is a common problem for individuals with inflammatory bowel disease (IBD). The aim of our study was to assess bone mineral density (BMD) in patients with IBD and to investigate the role of corticosteroid (CS) use and duration and activity of disease on BMD. Ninety-two patients (56 men and 36 women) with IBD, of whom 32 had ulcerative colitis (UC) and 60 had Crohn's disease (CD), underwent clinical assessment. Lumbar and femoral neck BMDs were measured by dual-energy X-ray absorptiometry. Osteopenia was observed in 14 patients (43%) with UC and in 24 patients (40%) with CD (p=0.187). Four patients (12%) with UC and 7 patients (11%) with CD had osteoporosis (p=0.308). Femoral BMD decreased in patients with long duration of CS use and correlated inversely with disease activity. Multiple regression analysis of BMD showed that statistically significant risk factors were duration of active disease and body mass index as well. Based on our results, it is necessary to take into account the risk of decreased BMD in patients with IBD. It is most important to achieve disease remission as soon as possible in addition to nutritional support.

1 Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Hospital Centre Rijeka, Rijeka, Croatia

2 Department of Gastroenterology, Clinical Hospital Centre Rijeka, Rijeka, Croatia

3 Department of Anatomy, Medical School, University of Rijeka, Rijeka, Croatia

4 Department of Physiology and Immunology, University of Rijeka, Rijeka, Croatia

Corresponding Author InformationAddress correspondence to: Zeljka Crncevic Orlic, M.D., Ph.D., Endocrinology Department, Clinic of Internal Medicine, University Hospital Rijeka, KBC Rijeka, Kresimirova 42, 51000 Rijeka, Croatia, Europe.

PII: S1094-6950(09)00271-6

doi:10.1016/j.jocd.2009.12.002


View previous. 6 of 105 View next.